Some of the data that’s coming out from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 will be helpful in figuring out where combination approaches can be utilized when it comes to treating patients with prostate cancer. Not to mention, that there are also PARP inhibitors and others that can be worked together with radiopharmaceutical therapy to prevent the cancer cells from regenerating after the damage occurred by radiopharmaceutical therapies. To learn more, join Dr. Munir Ghesani, Chief Medical Officer and Medical Director at United Theranostics in Princeton.
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Precision Strikes in Nuclear Medicine to Treat Prostate Cancer
Restart
Resume
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Comments
Recommended
Details
Presenters
Comments
Overview
Some of the data that’s coming out from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 will be helpful in figuring out where combination approaches can be utilized when it comes to treating patients with prostate cancer. Not to mention, that there are also PARP inhibitors and others that can be worked together with radiopharmaceutical therapy to prevent the cancer cells from regenerating after the damage occurred by radiopharmaceutical therapies. To learn more, join Dr. Munir Ghesani, Chief Medical Officer and Medical Director at United Theranostics in Princeton.